About Beijing Kangchen Pharmaceutical
Beijing Kangchen Pharmaceutical is a publicly listed company based in Beijing (China) founded in 2009. Antivenom drugs and pharmaceutical products are developed and manufactured. Its focus areas include Life Sciences, Toxicology, Drugs and Antivenom.
Company details
Beijing Kangchen Pharmaceutical was established in 2009 in Beijing, China, within the pharmaceutical sector. Antivenom drugs are developed as a primary focus, alongside the manufacturing of various pharmaceutical products. Operations are centered on research and production activities tailored to medical needs. The companys online presence is maintained through the domain konruns.cn, supporting its regional and international outreach in drug development.
- Headquarters Beijing, China
- Stage Public
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website konruns.cn
- Legal Name Beijing Konruns Pharmaceutical Co., Ltd. Class A
- Annual Revenue$129.79 M (USD)11as on Dec 31, 2025
- Net Profit$23.71 M (USD)293.13as on Dec 31, 2025
- EBITDA$30.81 M (USD)39.84as on Dec 31, 2025
IPO & Listings of Beijing Kangchen Pharmaceutical
Beijing Kangchen Pharmaceutical is a publicly listed company on the SSE with ticker symbol 603590 in China, operating in the Retail trade sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date27 Aug 2018
- Listed onSSE: 603590
- Listed entityBeijing Konruns Pharmaceutical Co., Ltd. Class A
- Exchange sectorRetail trade
- ISINCNE1000036K3
- Share price28.02 CNY (-4.04% on the day) · 2026-10-14
- Market capitalisation4,679,792,462.00 CNY
- Price to earnings26.0
- EPS (diluted, trailing year)1.08 CNY
- Dividend yield1.2%
- Volume (last session)3,480,614
Financials of Beijing Kangchen Pharmaceutical
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | 908.7M CNY | 166.0M CNY | 215.7M CNY |
| 2024 | 818.6M CNY | 42.2M CNY | 154.3M CNY |
| 2023 | 914.1M CNY | 150.4M CNY | 171.7M CNY |
| 2022 | 860.2M CNY | 101.5M CNY | 158.5M CNY |
| 2021 | 801.1M CNY | 148.0M CNY | 150.7M CNY |
Detailed financial statements for Beijing Kangchen Pharmaceutical
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Beijing Kangchen Pharmaceutical
Complete news archive for Beijing Kangchen Pharmaceutical
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Beijing Kangchen Pharmaceutical
Beijing Kangchen Pharmaceutical was founded in 2009.
Beijing Kangchen Pharmaceutical is headquartered in Beijing, China.
Annual revenue of Beijing Kangchen Pharmaceutical is $129.79M as on Dec 31, 2025.
Beijing Kangchen Pharmaceutical was established in 2009 in Beijing, China, within the pharmaceutical sector. Antivenom drugs are developed as a primary focus, alongside the manufacturing of various pharmaceutical products. Operations are centered on research and production activities tailored to medical needs. The companys online presence is maintained through the domain konruns.cn, supporting its regional and international outreach in drug development.
Yes, Beijing Kangchen Pharmaceutical is publicly traded on SSE under the ticker symbol 603590.